Biotech Startup Abcuro Raises $66M in Series D Funding

Abcuro, a Newton, MA-based clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases through precise modulation of cytotoxic T cells, has raised $66 million in a Series D funding round led by New Leaf Venture Partners.

The round also saw participation from abrdn Inc., Bain Capital Life Sciences, Samsara BioCapital, Redmile Group, Mass General Brigham Ventures, RA Capital Management, Pontifax, Sanofi Ventures, Foresite Capital, NEA, Eurofarma Ventures, Kaitai Capital, Soleus Capital, Nancy Chang, Shang Bay, and Rock Springs Capital.

The company will use the funding to advance clinical development of ulviprubart, an investigational monoclonal antibody targeting KLRG1 for patients with less severe Inclusion Body Myositis (IBM).

Funding Snapshot

About Abcuro

Founded as a clinical-stage biotechnology company, Abcuro develops targeted immunotherapies for debilitating and progressive rare autoimmune diseases.

Read More:Motor Vehicle-Based Grounded Raises $5M in Seed Funding

The company's approach focuses on precisely modulating cytotoxic T cells, which can play a role in driving autoimmune disease. Its lead program, ulviprubart, is designed to target killer cell lectin like receptor G1 (KLRG1).

Core offerings include:

• Targeted immunotherapies
• Cytotoxic T-cell modulation
• Ulviprubart clinical development
• Treatments for rare autoimmune diseases

Core Technologies / Products / Services